Kearney, Patricia M., et al. (2005). “Global burden of hypertension: analysis of worldwide data.” Lancet (London, England), vol. 365, 9455(2005): 217-23.
 Organization W. H. (2021). World health statistics 2021: monitoring health for the SDGs, sustainable development goals [M]. 2021: 39-40.
 Messerli, F. H., Bangalore, S., Bavishi, C., et al. (2018). Angiotensin-Converting Enzyme Inhibitors in Hypertension: To Use or Not to Use? [J]. Journal of the American College of Cardiology, 2018, 71(13): 1474-1482.
 Zhong, Y., Tang, R., Lu, Y., et al. (2020). Irbesartan may relieve renal injury by suppressing Th22 cells chemotaxis and infiltration in Ang II-induced hypertension. Int Immunopharmacol., 2020; 87: 106789.
 Whelton, P. K., Carey, R. M., Aronow, W. S., et al. (2017) ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/ PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines [published correction appears in Hypertension. 2018 Jun; 71(6):e140-e144]. Hypertension, 2018, 71(6): e13-e115.
 Gao Shuzhong, Yang Jun editor-in-chief. (2016). Acupuncture therapy [M]. Beijing: China Traditional Chinese Medicine Press, 2016, 43-44.
 Wu Zhaosu, Huo Yong, Wang Wen, et al. (2014). Guidelines for education of hypertension patients in China [J]. Journal of Chronic Diseases, 2014, 15(01):1-30.
 Chen Yuantao. (2008). Routine Diagnosis and Treatment of TCM Diseases and Syndromes [M]. Nanjing: Southeast University Press, 2008:66-67.
 Wang Jie, He Qingyong. (2011). Combination of disease and Syndrome with TCM Syndrome [M]. Beijing: China Medical Science and Technology Press, 2011: 32-40.
 (Song) by Chen Wuze. (2011). Beijing: China Medical Science and Technology Press, 2011 01.107.
 (Ming) by Yang Jizhou. (2008). Compendium of Acupuncture and Moxibustion [M]. Shanxi Publishing Group; Taiyuan: Shanxi Science and Technology Press, 2008: 78-368.
 Li Jing, Liu Xiaowei, Li Peipei, et al. (2020). Clinical observation of baihui point penetrating acupuncture combined with Western conventional therapy in the treatment of essential hypertension [J]. Journal of Traditional Chinese Medicine, 2020, 26(07): 38-41.
 Yuan Jingyun, Ji Zhi, Wang Zijuan, et al. (2019). Effects of electroacupuncture “Taichong” and “Baihui” on the expression of ACE2 and Ang(1-7) and the ratio of Ang(1-7)/Ang ⅱ in renal tissues of spontaneous hypertension rats [J]. Clinical Journal of Acupuncture and Moxibustion, 2019, 35(03): 46-50+89.
 Ding, L. (2018). Effects of different intensities of electroacupuncture at Fengchi and Quchi points on NF-κB P65 protein and gene expression in essential hypertension rats [J]. Journal of Shanxi University of Traditional Chinese Medicine, 2018, 19(03): 20-23+39.
 Li T, Ji B. (2020). Effect of pressure at Siguan point on blood pressure in adult prehypertensive population [J]. Zhejiang Journal of Traditional Chinese Medicine, 2020, 55(04): 256-257.
 Wang Jin, Chen Jie, He Ali. (2020). Effect of acupuncture at sanyinjiao and juangu points on immediate antihypertensive effect of renal essence deficiency hypertension [J]. Clinical Medical Research & Practice, 2020, 5(10): 115-116.
 Wang Jing, Lin Xiaojie, Luo Xiaozhou, et al. (2016). Acupuncture at Taixi point reduces SHR blood pressure and regulates TNF-α and IL-6 protein expression in medulla oblongata [J]. Journal of Jinan University (Natural Science & Medicine), 2016, 37(04): 327-330.
 Shi Wai, Liu Boxun, Kong Xiangqing. (2020). Review of the international Society of Hypertension 2020 International Practice Guidelines for Hypertension [J]. Chinese Journal of Hypertension, 2020, 28(10): 912-914.
 Sanchis-Gomar, F., Lavie, C. J., Perez-Quilis, C., et al. (2019). Angiotensin-Converting Enzyme 2 and Antihypertensives (An-giotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019 [J]. MAYO Clinic Proceedings, 2020, 95(6): 1222-1230.